Targets › EBP
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2029.
Isomerase that catalyzes the conversion of Delta(8)-sterols to their corresponding Delta(7)-isomers a catalytic step in the postlanosterol biosynthesis of cholesterol..; FUNCTION: Component of the microsomal antiestrogen binding site (AEBS), a multiproteic complex at the ER membrane that consists of an association between EBP and 7-dehydrocholesterol reductase/DHCR7. This complex is responsible for…. (UniProt, Q15125)
Open in Phaseline: the race on EBP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Washington University School of Medicine | DSP-0390 EBP (emopamil binding protein) inhibitor; inhibits de novo cholesterol synthesis | EBP | Phase 1 | Small-cell Lung Cancer | Sep 2029 |
Small-cell Lung Cancer (1)
mixed (1)
Washington University School of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.